A Quantum Dot Probe Conjugated with Aβ Antibody for Molecular Imaging of Alzheimer’s Disease in a Mouse Model

Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia

(2012) Peder Buchhave   ARCHIVES OF GENERAL PSYCHIATRY

Neuropathology after active Aβ42 immunotherapy: implications for Alzheimer’s disease pathogenesis

(2010) Delphine Boche et al.   ACTA NEUROPATHOLOGICA

Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot study

(2010) Felix Bermejo-Pareja et al.   BMC Neurology

Differential levels of  -synuclein,  -amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease

(2010) K. Kasuga et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Genome-wide association study of CSF biomarkers A 1-42, t-tau, and p-tau181p in the ADNI cohort

(2010) S. Kim et al.   NEUROLOGY

Quantum Dots for Live Cell and In Vivo Imaging

(2009) Maureen Walling et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Use of CSF biomarkers in Alzheimer’s disease clinical trials

(2009) K. Blennow et al.   Journal of Nutrition Health & Aging

Bioconjugated Quantum Rods as Targeted Probes for Efficient Transmigration Across an in Vitro Blood−Brain Barrier

(2008) Gaixia Xu et al.   BIOCONJUGATE CHEMISTRY

The biocompatibility of quantum dot probes used for the targeted imaging of hepatocellular carcinoma metastasis

(2008) Liang-Dong Chen et al.   BIOMATERIALS

Diagnostic et prise en charge de la maladie d Alzheimer et des maladies apparentees

(2008)   REVUE NEUROLOGIQUE